PD-1 inhibitors enhance future value of anticancer treatment
By | translator Alice Kang
21.06.21 06:00:32
가나다라
0
[Interview] Professor Eui-Cheol Shin, Graduate School of Medical Science and Engineering,
Korea Advanced Institute of Science and Technology (KAIST)
Korea Advanced Institute of Science and Technology (KAIST)
PD-(L)1 is the strongest biomarker…personalized cancer vaccines may work as alternative when developing resistance
Immunotherapy+immunotherapy combination may be a good option that makes up for the other therapy's shortcoming
▲Professor Eui-Cheol Shin
Since its first appearance in 2011, cancer immunotherapies have opened a new paradigm in the field of cancer treatment. Moving on from the era of targeted therapies that target specific gene mutation, the new era had opened where a patient’s immune system is activated to remove the malignant tumor.The immunotherapies that have been commercialized until now, such as Opdivo, Yervoy, and Keytruda, are all immune checkpoint inhibitors that target immunomodulators such as CTLA-4 or PD-(L)1. Immunologists Professor James P. Allison and Professor Tasuku Honjo were jointly awarded the Nobel Prize in Physiology or Medicine in 2018 for their discovery of this mechanism.
In the wide and complex f
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)